按需吸入性糖皮质激素治疗哮喘:ATS临床实践指南
美国胸科学会(ATS)针对青少年和成人哮喘患者,按NAEPP治疗步骤1-5,系统评价含ICS缓解治疗。指南强烈推荐步骤1-2使用按需ICS-SABA或ICS-福莫特罗优于单用SABA,步骤3-5强烈推荐MART优于固定ICS-LABA加按需SABA。
要点
- 步骤1-2:强烈推荐按需ICS-SABA或ICS-福莫特罗优于单用SABA。
- 步骤3-5:强烈推荐ICS-福莫特罗MART优于固定ICS-LABA加按需SABA。
- 固定ICS-LABA者:条件推荐ICS+SABA缓解优于单用SABA缓解。
核心结论
- 指南基于系统评价和GRADE证据,对含ICS缓解治疗在哮喘中的安全有效使用提出推荐。
研究设计与样本
- ATS临床实践指南小组以PICO格式评价六个研究问题,覆盖NAEPP步骤1-5。
- 方法学团队进行系统文献综述和GRADE评估,小组据此形成推荐。
主要发现
- 步骤1-2:强烈推荐按需ICS-SABA或ICS-福莫特罗优于单用SABA。
- 步骤1-2:条件推荐按需ICS-SABA或ICS-福莫特罗优于计划ICS加按需SABA。
- 步骤3-5:强烈推荐ICS-福莫特罗MART优于计划ICS-LABA加按需SABA。
- 步骤3-5使用计划ICS-LABA者:条件推荐ICS+SABA缓解优于SABA缓解。
关键数值与推荐
- 推荐适用于NAEPP步骤1-5的青少年和成人哮喘患者。
- 小组重视预防重度急性发作,并考虑单用SABA治疗风险及ICS和SCS暴露。
临床怎么用
- 对步骤1-2患者,可选用按需ICS-SABA或ICS-福莫特罗替代单用SABA。
- 对步骤3-5患者,优先采用ICS-福莫特罗MART方案。
- 对已用计划ICS-LABA的步骤3-5患者,缓解治疗应选用ICS+SABA而非单用SABA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhaled corticosteroid (ICS)-containing reliever therapy has demonstrated efficacy in improving asthma outcomes when compared to short-acting beta2-agonists (SABA) alone but remains underutilized. The purpose of this guideline is to provide recommendations surrounding the use of combination ICS-formoterol or ICS+SABA (in combination or separate inhalers) as reliever therapy across the asthma severity spectrum in adolescents and adults. METHODS: The American Thoracic Society clinical practice guideline panel evaluated six research questions in the PICO format addressing the use of ICS-containing reliever therapy across National Asthma Education and Prevention Program (NAEPP) asthma treatment steps 1-5. The methodology team conducted systematic literature reviews and GRADE assessments, which the panel utilized to inform the recommendations for each specific PICO and overall. RECOMMENDATIONS: In patients at NAEPP steps 1 and 2, the panel made strong recommendations for the use of as-needed-only ICS-SABA or ICS-formoterol over SABA-only therapy, and conditional recommendations over scheduled ICS + as-needed SABA. In patients at NAEPP steps 3-5, the taskforce made a strong recommendation for the use of maintenance-and-reliever therapy (MART) with ICS-formoterol over scheduled ICS-LABA plus as-needed SABA. In patients at NAEPP steps 3-5 who are using scheduled maintenance ICS-LABA, the panel made a conditional recommendation for use of ICS+SABA reliever over SABA reliever. In considering these recommendations, the panel valued the importance of preventing severe exacerbations and considered the risk of SABA-only treatment, as well as ICS and systemic corticosteroid (SCS) exposure. CONCLUSIONS: This clinical practice guideline, informed by systematic reviews and GRADE-based appraisals of PICO-framed evidence, makes these evidence-based recommendations for the safe and effective use of ICS-containing reliever therapy in asthma.
引用
- Khurana S, Jenkins AR, Reddel HK, et al. As-needed inhaled corticosteroids in asthma: an Official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2026. PMID: 42974958. doi:10.1093/ajrccm/aamag577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。